S&P 500   3,380.24 (+0.51%)
DOW   27,814.12 (+0.12%)
QQQ   282.10 (+1.53%)
AAPL   116.65 (+0.73%)
MSFT   212.96 (+1.25%)
FB   267.45 (+2.12%)
GOOGL   1,486.82 (+1.45%)
AMZN   3,200.88 (+1.66%)
TSLA   446.12 (+3.99%)
NVDA   544.00 (+0.51%)
BABA   290.62 (-1.14%)
CGC   14.13 (-1.33%)
MU   47.75 (+1.68%)
GE   6.18 (-0.80%)
AMD   84.88 (+3.52%)
T   28.48 (-0.11%)
F   6.71 (+0.75%)
ACB   4.74 (+1.94%)
GILD   63.37 (+0.28%)
NFLX   519.85 (+3.96%)
DIS   123.65 (-0.35%)
BA   166.53 (+0.77%)
BAC   24.03 (-0.25%)
S&P 500   3,380.24 (+0.51%)
DOW   27,814.12 (+0.12%)
QQQ   282.10 (+1.53%)
AAPL   116.65 (+0.73%)
MSFT   212.96 (+1.25%)
FB   267.45 (+2.12%)
GOOGL   1,486.82 (+1.45%)
AMZN   3,200.88 (+1.66%)
TSLA   446.12 (+3.99%)
NVDA   544.00 (+0.51%)
BABA   290.62 (-1.14%)
CGC   14.13 (-1.33%)
MU   47.75 (+1.68%)
GE   6.18 (-0.80%)
AMD   84.88 (+3.52%)
T   28.48 (-0.11%)
F   6.71 (+0.75%)
ACB   4.74 (+1.94%)
GILD   63.37 (+0.28%)
NFLX   519.85 (+3.96%)
DIS   123.65 (-0.35%)
BA   166.53 (+0.77%)
BAC   24.03 (-0.25%)
S&P 500   3,380.24 (+0.51%)
DOW   27,814.12 (+0.12%)
QQQ   282.10 (+1.53%)
AAPL   116.65 (+0.73%)
MSFT   212.96 (+1.25%)
FB   267.45 (+2.12%)
GOOGL   1,486.82 (+1.45%)
AMZN   3,200.88 (+1.66%)
TSLA   446.12 (+3.99%)
NVDA   544.00 (+0.51%)
BABA   290.62 (-1.14%)
CGC   14.13 (-1.33%)
MU   47.75 (+1.68%)
GE   6.18 (-0.80%)
AMD   84.88 (+3.52%)
T   28.48 (-0.11%)
F   6.71 (+0.75%)
ACB   4.74 (+1.94%)
GILD   63.37 (+0.28%)
NFLX   519.85 (+3.96%)
DIS   123.65 (-0.35%)
BA   166.53 (+0.77%)
BAC   24.03 (-0.25%)
S&P 500   3,380.24 (+0.51%)
DOW   27,814.12 (+0.12%)
QQQ   282.10 (+1.53%)
AAPL   116.65 (+0.73%)
MSFT   212.96 (+1.25%)
FB   267.45 (+2.12%)
GOOGL   1,486.82 (+1.45%)
AMZN   3,200.88 (+1.66%)
TSLA   446.12 (+3.99%)
NVDA   544.00 (+0.51%)
BABA   290.62 (-1.14%)
CGC   14.13 (-1.33%)
MU   47.75 (+1.68%)
GE   6.18 (-0.80%)
AMD   84.88 (+3.52%)
T   28.48 (-0.11%)
F   6.71 (+0.75%)
ACB   4.74 (+1.94%)
GILD   63.37 (+0.28%)
NFLX   519.85 (+3.96%)
DIS   123.65 (-0.35%)
BA   166.53 (+0.77%)
BAC   24.03 (-0.25%)
Log in
NASDAQ:SYRS

Syros Pharmaceuticals Stock Forecast, Price & News

$8.83
-0.01 (-0.11 %)
(As of 10/1/2020 02:35 PM ET)
Add
Compare
Today's Range
$8.64
Now: $8.83
$9.21
50-Day Range
$8.69
MA: $11.26
$14.47
52-Week Range
$4.26
Now: $8.83
$14.69
Volume15,272 shs
Average Volume332,046 shs
Market Capitalization$404.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Read More
Syros Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYRS
CUSIPN/A
Phone617-744-1340

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.98 million
Book Value$1.87 per share

Profitability

Net Income$-75,440,000.00
Net Margins-1,114.79%

Miscellaneous

Employees76
Market Cap$404.08 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$8.83
-0.01 (-0.11 %)
(As of 10/1/2020 02:35 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

How has Syros Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SYRS stock has increased by 71.5% and is now trading at $8.83.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Syros Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Syros Pharmaceuticals
.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Syros Pharmaceuticals
.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals Inc (NASDAQ:SYRS) announced its earnings results on Thursday, August, 6th. The company reported ($0.38) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.02. The company had revenue of $3.19 million for the quarter, compared to analysts' expectations of $2.19 million. Syros Pharmaceuticals had a negative net margin of 1,114.79% and a negative return on equity of 94.59%.
View Syros Pharmaceuticals' earnings history
.

What price target have analysts set for SYRS?

7 brokerages have issued 12 month price objectives for Syros Pharmaceuticals' shares. Their forecasts range from $9.00 to $20.00. On average, they expect Syros Pharmaceuticals' share price to reach $15.00 in the next twelve months. This suggests a possible upside of 69.9% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals
.

Are investors shorting Syros Pharmaceuticals?

Syros Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 3,620,000 shares, an increase of 31.2% from the August 15th total of 2,760,000 shares. Based on an average daily trading volume, of 366,600 shares, the days-to-cover ratio is presently 9.9 days. Currently, 9.1% of the shares of the company are short sold.
View Syros Pharmaceuticals' Short Interest
.

Who are some of Syros Pharmaceuticals' key competitors?

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD), ImmunoGen (IMGN), Nektar Therapeutics (NKTR), Amarin (AMRN), GlycoMimetics (GLYC) and Pfizer (PFE).

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)
  • Dr. David A. Roth, Chief Medical Officer (Age 56)
  • Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)
  • Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $8.83.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $404.08 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is www.syros.com.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.